Cargando…

An NMR Study of the Bortezomib Degradation under Clinical Use Conditions

The (R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl-boronic acid, bortezomib (BTZ), which binds the 20S proteasome subunit and causes a large inhibition of its activity, is a peptidomimetic boronic drug mainly used for the treatment of multiple myeloma. Commercial BTZ, stabi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bolognese, Adele, Esposito, Anna, Manfra, Michele, Catalano, Lucio, Petruzziello, Fara, Martorelli, Maria Carmen, Pagliuca, Raffaella, Mazzarelli, Vittoria, Ottiero, Maria, Scalfaro, Melania, Rotoli, Bruno
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778348/ https://www.ncbi.nlm.nih.gov/pubmed/19960052 http://dx.doi.org/10.1155/2009/704928

Ejemplares similares

An (1)H NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia
por: Cerchione, Claudio, et al.
Publicado: (2020)

Nodular goiter with amyloid deposition in an elderly patient: fine-needle cytology diagnosis and review of the literature
por: Di Crescenzo, Vincenzo, et al.
Publicado: (2013)

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
por: Cerchione, Claudio, et al.
Publicado: (2016)

Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone
por: Cerchione, Claudio, et al.
Publicado: (2016)

Bortezomib in autoimmune hemolytic anemia and beyond
por: Pasquale, Raffaella, et al.
Publicado: (2021)

Dual Blockade of Misfolded Alpha-Sarcoglycan Degradation by Bortezomib and Givinostat Combination
por: Hoch, Lucile, et al.
Publicado: (2022)

Bortezomib
por: Rajappa, Senthil
Publicado: (2010)

Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations
por: Liu, Jianhao, et al.
Publicado: (2021)

LC and NMR Studies for Identification and Characterization of Degradation Byproducts of Olmesartan Acid, Elucidation of Their Degradation Pathway and Ecotoxicity Assessment
por: Luongo, Giovanni, et al.
Publicado: (2021)

Hypereosinophilia in childhood acute lymphoblastic leukaemia at diagnosis: report of 2 cases and review of the literature
por: Parasole, Rosanna, et al.
Publicado: (2014)

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
por: Richard, Shambavi, et al.
Publicado: (2021)

Bortezomib in Kidney Transplantation
por: Raghavan, Rajeev, et al.
Publicado: (2010)

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
por: Spencer, Andrew, et al.
Publicado: (2018)

Bortezomib enhances radiosensitivity in oral cancer through inducing autophagy-mediated TRAF6 oncoprotein degradation
por: Wu, Yuan-Hua, et al.
Publicado: (2018)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
por: Petrucci, Maria Teresa, et al.
Publicado: (2014)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

An Overview of Bortezomib-Induced Neurotoxicity
por: Meregalli, Cristina
Publicado: (2015)

Combined Effect of Bortezomib and Menadione Sodium Bisulfite on Proteasomes of Tumor Cells: The Dramatic Decrease of Bortezomib Toxicity in a Preclinical Trial
por: Astakhova, Tatiana M., et al.
Publicado: (2018)

Cap dependent translation contributes to resistance of myeloma cells to bortezomib
por: Mancino, Marilena, et al.
Publicado: (2013)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
por: O’Connor-Byrne, N., et al.
Publicado: (2019)

β-catenin inhibitors ICG-001 and pyrvinium sensitize bortezomib-resistant multiple myeloma cells to bortezomib
por: Wu, Cuicui
Publicado: (2022)

ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5
por: Yang, Yan, et al.
Publicado: (2022)

Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2/M transition and MCL-1 degradation
por: Rapino, F, et al.
Publicado: (2013)

Flavokawain B targets protein neddylation for enhancing the anti-prostate cancer effect of Bortezomib via Skp2 degradation
por: Li, Xuesen, et al.
Publicado: (2019)

Upregulation of Protein Synthesis and Proteasome Degradation Confers Sensitivity to Proteasome Inhibitor Bortezomib in Myc-Atypical Teratoid/Rhabdoid Tumors
por: Tran, Huy Minh, et al.
Publicado: (2020)

Omega-3 Fatty Acids DHA and EPA Reduce Bortezomib Resistance in Multiple Myeloma Cells by Promoting Glutathione Degradation
por: Chen, Jing, et al.
Publicado: (2021)

Interaction of Bortezomib with Cell Membranes Regulates Its Toxicity and Resistance to Therapy
por: Ramalho, Maria João, et al.
Publicado: (2022)

Emerging Therapeutic RNAs for the Targeting of Cancer Associated Fibroblasts
por: Santana-Viera, Laura, et al.
Publicado: (2020)

Advances in Oligonucleotide Aptamers for NSCLC Targeting
por: Rotoli, Deborah, et al.
Publicado: (2020)

Hypoxia Selects Bortezomib-Resistant Stem Cells of Chronic Myeloid Leukemia
por: Tanturli, Michele, et al.
Publicado: (2011)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Bortezomib Induced Hepatitis B Reactivation
por: Hussain, Salwa, et al.
Publicado: (2014)

The resistance mechanisms of proteasome inhibitor bortezomib
por: Lü, Shuqing, et al.
Publicado: (2013)

Why bortezomib cannot go with ‘green’?
por: Jia, Li, et al.
Publicado: (2013)

Herpes zoster complicating bortezomib therapy
por: Sahu, Kamal Kant, et al.
Publicado: (2015)

Response of Bortezomib Chemotherapy in Hepatic Amyloidosis
por: Hasan, Syed M., et al.
Publicado: (2018)

Clinical manifestations of intravitreal bortezomib injection
por: Nguyen, Chan, et al.
Publicado: (2020)

Development and characterization of liposomal formulation of bortezomib
por: Deshantri, Anil K., et al.
Publicado: (2019)

NMR Spectroscopy of Macrophages Loaded with Native, Oxidized or Enzymatically Degraded Lipoproteins
por: Ramm Sander, Paul, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_prn3idjt1nn109rascqggu5730